JAZZ ▼ -0.8% - Jazz Pharmaceuticals plc
$JAZZ JAZZ - Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
23-OCT-2026 10:15 AM ET
Share this post
More filings for $JAZZ
JAZZ ▲ +0.3% - Jazz Pharmaceuticals plcNov 12, 2026JAZZ - Jazz Pharmaceuticals plc - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026JAZZ ▲ +7.1% - Jazz Pharmaceuticals plcNov 3, 2026JAZZ ▼ -0.6% - Jazz Pharmaceuticals plcNov 2, 2026JAZZ ▼ -0.1% - Jazz Pharmaceuticals plcNov 2, 2026JAZZ ▲ +0.5% - Jazz Pharmaceuticals plcSep 15, 2026
View full $JAZZ filing history →💬 Comments
Loading comments…
Leave a comment